Modafinil
Postpoliomyelitis Syndrome
National Institute of Neurological Disorders and Stroke (NINDS)Small moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Postpoliomyelitis Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
L-Carnitine | Phase 3 | B |
Piracetam | Phase 3 | CC |
Xepol Calliditas Therapeutics AB | N/A | NR |
Same molecule, other indications
Modafinil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →